Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Short Interest Update

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 3,620,000 shares, a decrease of 16.0% from the December 15th total of 4,310,000 shares. Based on an average trading volume of 3,270,000 shares, the short-interest ratio is currently 1.1 days.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MRNS shares. StockNews.com started coverage on Marinus Pharmaceuticals in a research report on Monday. They issued a “sell” rating for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 target price (down from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS traded down $0.00 during midday trading on Thursday, reaching $0.54. The stock had a trading volume of 574,063 shares, compared to its average volume of 2,054,186. The company’s fifty day simple moving average is $0.36 and its two-hundred day simple moving average is $1.00. The company has a market cap of $29.88 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 DIFC Ltd acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $28,000. AQR Capital Management LLC boosted its holdings in Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $64,000. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals during the third quarter worth approximately $104,000. Finally, Squarepoint Ops LLC acquired a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $206,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.